Editas Medicine, Inc. (NASDAQ:EDIT) EVP Sells $34,484.99 in Stock

Editas Medicine, Inc. (NASDAQ:EDIT) EVP Baisong Mei sold 6,619 shares of the stock in a transaction on Friday, July 19th. The shares were sold at an average price of $5.21, for a total transaction of $34,484.99. Following the transaction, the executive vice president now owns 134,413 shares of the company’s stock, valued at approximately $700,291.73. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Baisong Mei also recently made the following trade(s):

• On Tuesday, June 4th, Baisong Mei sold 511 shares of Editas Medicine stock. The shares were sold at an average price of $5.50, for a total transaction of $2,810.50.

Editas Medicine Price Performance

Shares of NASDAQ:EDIT traded up $0.21 during trading hours on Monday, hitting $5.21. The company’s stock had a trading volume of 1,853,384 shares, compared to its average volume of 1,956,523. The firm’s fifty day moving average price is $5.29 and its 200 day moving average price is $6.72. Editas Medicine, Inc. has a 52 week low of $4.45 and a 52 week high of $11.69. The company has a market capitalization of $428.47 million, a price-to-earnings ratio of -2.38 and a beta of 2.01.

Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.13). The business had revenue of $1.10 million during the quarter, compared to the consensus estimate of $11.14 million. Editas Medicine had a negative return on equity of 47.34% and a negative net margin of 239.36%. The business’s quarterly revenue was down 88.9% on a year-over-year basis. During the same period last year, the firm earned ($0.71) EPS. On average, equities research analysts predict that Editas Medicine, Inc. will post -2.7 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Editas Medicine

A number of hedge funds have recently made changes to their positions in EDIT. Russell Investments Group Ltd. grew its stake in Editas Medicine by 401.9% in the fourth quarter. Russell Investments Group Ltd. now owns 5,190 shares of the company’s stock valued at $53,000 after purchasing an additional 4,156 shares during the last quarter. Hoylecohen LLC bought a new stake in shares of Editas Medicine in the 2nd quarter valued at about $55,000. Spectrum Planning & Advisory Services Inc. purchased a new position in shares of Editas Medicine in the 2nd quarter worth approximately $57,000. Headlands Technologies LLC raised its stake in shares of Editas Medicine by 481.7% during the 1st quarter. Headlands Technologies LLC now owns 9,493 shares of the company’s stock worth $70,000 after acquiring an additional 7,861 shares in the last quarter. Finally, EntryPoint Capital LLC purchased a new stake in Editas Medicine during the first quarter valued at approximately $72,000. 71.90% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on EDIT. StockNews.com cut Editas Medicine from a “hold” rating to a “sell” rating in a research note on Thursday, May 9th. Morgan Stanley raised Editas Medicine from an “underweight” rating to an “equal weight” rating and set a $7.00 target price on the stock in a research report on Thursday, May 9th. Oppenheimer reaffirmed a “market perform” rating and set a $12.00 price objective on shares of Editas Medicine in a research note on Tuesday, June 18th. Evercore ISI reduced their target price on shares of Editas Medicine from $15.00 to $7.00 and set an “in-line” rating on the stock in a research note on Thursday, May 30th. Finally, Barclays dropped their target price on Editas Medicine from $11.00 to $9.00 and set an “equal weight” rating for the company in a research report on Thursday, May 9th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Editas Medicine currently has a consensus rating of “Hold” and an average target price of $12.90.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.